Bernice Kwong, MD, clinical professor of dermatology, Stanford University, expands on her session about graft-versus-host disease diagnosis and management presented at the 2022 American Academy of Dermatology Annual Meeting, emphasizing the importance of the relationship between patients and doctors.
Clinical trial recruitment and management strategies for diverse populations are among the challenges that affect dermatology care quality and access, according to panelists at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Panelists reviewed the latest advancements in clinical testing for melanoma, targeted therapy implications, and strategies for patient selection at a session on genetic and molecular testing at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center, discusses best practices for choosing biologics, as well as his late-breaking findings on ruxolitinib cream for vitiligo at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, sat down to discuss comorbidities newly associated with atopic dermatitis at the 2022 American Academy of Dermatology Annual Meeting.
A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.
Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.
Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.
Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.
The lack of racial representation in dermatology education prompted the launch of Project IMPACT, explained Art Papier, MD, dermatologist, CEO, VisualDx at the 2022 American Academy of Dermatology Annual Meeting.
Angela Storseth-Cooper, associate director, Government Relations & Public Policy, The US Oncology Network, discusses state-level legislation that community oncology practices can leverage to address issues involving pharmacy benefit managers and the vertical integration of health plans and specialty pharmacies.
The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty pharmaceutical pipeline, with a featured preconference session on bias in health care.
The Pharmacy Quality Alliance's 2022 annual meeting will return to an in-person format after 2 years. The meeting with include timely topics: quality beyond the pandemic, health equity, and remote care
At the 2022 Community Oncology Conference, Elizabeth Spurlock, MA, PHR, director, Human Resources Business Partner, Texas Oncology, discussed the prevalence of burnout among physicians, staff, and administrators, and several strategies to reduce risk and support the health care workforce.
Emerging research on therapeutics and practical approaches to managing a myriad of dermatological conditions, as well as a growing focus on diversity, equity, and inclusion will be explored at the 2022 American Academy of Dermatology (AAD) Annual Meeting, which will take place March 25-29, in Boston, Massachusetts.
Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Quality measures are the lifeblood of practice transformation, but learning which ones make a difference—and how to use them to drive change—is as much an art as a science, according to 3 oncology care leaders who discussed the topic Friday at the 2022 Community Oncology Conference, presented by the Community Oncology Alliance.
During a panel at the Community Oncology Alliance’s Community Oncology Conference, speakers discuss practice-level efforts to reduce cancer care disparities.
Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network, speaks on how use of health economics and outcomes research has benefitted patient care in the community oncology setting and where it can be further leveraged in the pursuit of value-based care.
Jim Schwartz, RPh, corporate pharmacy manager, Texas Oncology, discussed pharmacy challenges regarding equitable care and distribution of specialty drugs in the community oncology setting.
Barbara McAneny, MD, CEO of the New Mexico Cancer Center, who served as president of the American Medical Association (AMA) in 2018, said the AMA has engaged a law firm to take on the issue of curtailing prior authorization, which oncologists say has become worse with increased vertical integration among health plans and pharmacy benefit managers.
Ben Jones, vice president, Government Relations & Public Policy, The US Oncology Network, addresses potential reform at the federal and state level that could accelerate the pursuit of value-based care in the community oncology setting.
A panel on the first day of the Community Oncology Alliance 2022 Community Oncology Conference examines issues that will affect oncology practices in the future.
Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, speaks on takeaways from his discussions on site of care and pharmacy benefit managers (PBMs) at the 2022 Community Oncology Conference.
The first in-person Community Oncology Alliance (COA) meeting in 2 years will feature sessions on practice management, health disparities, and more. A virtual option is available.
Kashyap Patel, MD, chief executive officer, Carolina Blood and Cancer Care Associations, and current president of the Community Oncology Alliance (COA), previews his discussion on health equity to be held at the 2022 Community Oncology Conference.
Glenn Balasky, executive director of Rocky Mountain Cancer Centers, previewed topics and potential takeaways from his discussion on building a community oncology practice for the future at the 2022 Community Oncology Conference.
David Penberthy, MD, MBA, medical director of radiation oncology at Southside Regional Medical Center, discusses his theme as president-elect of the Association of Community Cancer Centers (ACCC) and what initiatives and discussions he looks forward to addressing over the next year.
A session moderated by the president of the Association of Community Cancer Centers (ACCC) examined the business case for having oncology pharmacists and oncology social workers on community cancer care teams.
The panel said the prior authorization system was intended not just to make sure treatments are necessary but also to ensure that practices get paid; however, it needs a lot of work.
